Evaluation of Efficacy, Safety & Immunogenicity of GX-19N in Healthy

See also
Status	Clinical Trial	Phase
Completed	`NCT04979858` - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask	N/A
Recruiting	`NCT05311410` - Viral Kinetics of SARS-CoV-2 in Patients With COVID-19 in the Intensive Care Unit Undergoing Dental Procedures	N/A
Active, not recruiting	`NCT05073718` - SARS-CoV-2 and Acetylsalicylic Acid (SARA)	Phase 3
Completed	`NCT05055505` - The School SPIT Study - Elementary Schools in Low COVID-19 Incidence Regions	N/A
Completed	`NCT05055492` - The School SPIT Study - Elementary Schools in High COVID-19 Incidence Regions	N/A
Completed	`NCT05060510` - The School SPIT Study - COVID-19 Testing in Secondary Schools	N/A
Completed	`NCT05054218` - COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients
Completed	`NCT05449392` - Topical Antibacterial Agents for Prevention of COVID-19	Phase 1
Completed	`NCT05076253` - Efficacy of Ivermectin in COVID-19	Phase 1/Phase 2
Recruiting	`NCT05172024` - Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)
Terminated	`NCT05593770` - International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response	Phase 2/Phase 3
Completed	`NCT05030974` - RECOVAC Repeated Vaccination Study	Phase 4
Not yet recruiting	`NCT05013034` - Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients	Phase 2
Withdrawn	`NCT05393999` - SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations	Phase 2
Recruiting	`NCT05047783` - Masitinib in Patients With Symptomatic Mild to Moderate COVID-19	Phase 2
Not yet recruiting	`NCT05116657` - Obstructive Sleep Apnoea Post Covid 19: Role of the Upper Airway Microbiome
Recruiting	`NCT04590222` - Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19
Completed	`NCT04551911` - Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19	Phase 2
Completed	`NCT04953039` - Use of Saliva for COVID-19 Diagnosis
Active, not recruiting	`NCT06181292` - Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine	Phase 2/Phase 3

NCT number	NCT05067946
Study type	Interventional
Source	Genexine, Inc.
Contact
Status	Withdrawn
Phase	Phase 2/Phase 3
Start date	October 2021
Completion date	October 2023

Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms